{"id":"atb-346-mid-dose","safety":{"commonSideEffects":[{"rate":"null","effect":"Gastrointestinal upset"}]},"_chembl":{"chemblId":"CHEMBL4211107","moleculeType":"Small molecule","molecularWeight":"365.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ATB-346 mid-dose works by inhibiting the COX-2 enzyme, which is responsible for producing prostaglandins that cause inflammation and pain. By selectively targeting COX-2, ATB-346 mid-dose aims to reduce gastrointestinal toxicity associated with traditional NSAIDs. This mechanism is intended to provide analgesic and anti-inflammatory effects while minimizing the risk of gastrointestinal side effects.","oneSentence":"ATB-346 mid-dose is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets COX-2 to reduce gastrointestinal toxicity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:45.798Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of osteoarthritis"}]},"trialDetails":[{"nctId":"NCT03978208","phase":"PHASE2","title":"Efficacy and Safety of ATB-346 Versus Placebo in Osteoarthritis Patients","status":"COMPLETED","sponsor":"Antibe Therapeutics Inc.","startDate":"2019-03-29","conditions":"Osteoarthritis","enrollment":381}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Active comparator"],"phase":"phase_2","status":"active","brandName":"ATB-346 mid-dose","genericName":"ATB-346 mid-dose","companyName":"Antibe Therapeutics Inc.","companyId":"antibe-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATB-346 mid-dose is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets COX-2 to reduce gastrointestinal toxicity. Used for Treatment of osteoarthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}